Annovis Bio (ANVS) vs Elicio Therapeutics (ELTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Annovis Bio (ANVS) has outperformed Elicio Therapeutics (ELTX) over the past year, losing 48.5% versus a loss of 82.8%. Over five years, ANVS leads with a -95.8% price change compared with -97.9% for ELTX. Annovis Bio is the larger company by market cap ($49.9 million vs $47.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANVS | ELTX |
|---|---|---|
| Share price | $1.17 | $1.81 |
| Market cap | $49.93M | $47.57M |
| 1-day change | -3.31% | -2.16% |
| YTD return | -66.18% | -77.26% |
| 1-year return | -48.46% | -82.79% |
| 5-year return | -95.82% | -97.92% |
| EPS (TTM) | $-1.75 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.50 | $16.00 |
| 52-week low | $1.04 | $1.71 |
| Distance from 52-week high | -78.73% | -88.69% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +797.44% | +655.25% |
| Average volume | 884.63K | 340.72K |
| Shares outstanding | 42.68M | 26.28M |
| Employees | 7 | 33 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANVS has outperformed ELTX by 34.3 percentage points over the past year.
About Annovis Bio
ANVS stock →Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.
Healthcare · Biotechnology · 7 employees
About Elicio Therapeutics
ELTX stock →Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Healthcare · Biotechnology · 33 employees
ANVS vs ELTX FAQ
Which is bigger, Annovis Bio or Elicio Therapeutics?
Annovis Bio (ANVS) is larger, with a market capitalization of $49.93M compared with $47.57M for Elicio Therapeutics (ELTX).
Which stock has performed better over the past year, ANVS or ELTX?
ANVS returned -48.46% over the past 12 months, compared with -82.79% for ELTX (price return, excluding dividends). Past performance does not predict future results.
Are Annovis Bio and Elicio Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.